MedTrace Logo

Exploring a Potential Blood Test to Diagnose Major Depressive Disorder

NCT00705185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2010-06-08

No results posted yet for this study

Summary

The purpose of this study is to develop a blood test for major depression and measure the effects of ziprasidone monotherapy on these markers.

Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in patients with MDD enrolled in this ancillary study (adjunct to study NCT00555997) and compare these results to those of healthy controls" (defined as research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.

Conditions

Sponsors & Collaborators

  • Precision Human Biolaboratories

    collaborator UNKNOWN

  • Cambridge Health Alliance

    collaborator OTHER

  • University of Connecticut

    collaborator OTHER

  • Vanderbilt University

    collaborator OTHER

  • Psychiatric Medicine Associates, L.L.C.

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • George I Papakostas, M.D. · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705185 on ClinicalTrials.gov